Startups

Incyte snags rights to blood disease drug

The Wilmington biopharma company will be studying how ruxolitinib could treat graft-versus-host disease, an opportunity they bought for a cool $35 million.

Red blood cells. (Photo by Flickr user Wellcome Images, used under a Creative Commons license)

The Wilmington-based biopharmaceutical company Incyte Corporation announced this week that it has bought the rights to develop and commercialize a drug with the potential to treat people suffering from graft-versus-host disease, which happens when transplanted blood attacks the body’s organs.
Hervé Hoppenot, Incyte’s president and CEO, said in a release that there are currently no approved treatments for the disease, which often causes death. The organs graft-versus-host most commonly targets are the skin, digestive tract and liver.
Incyte bought rights to the drug, called ruxolitinib, commercially known as Jakafi, from Ely Lilly and Company for an upfront $35 million, according to a release from Incyte.
In addition to the deal with Ely Lilly, Incyte also granted Swiss pharmaceutical company Novartis rights to research, develop and commercialize Jakafi outside of the United States. In both agreements, money changes hands when regulatory milestones for the drug happen, going from Incyte to Ely Lilly and from Novartis to Incyte.
Jakafi has been approved by the FDA to treat people with the bone marrow diseases polycythemia vera and myelofibrosis, but it’s not approved anywhere to treat graft-versus-host.
Hoppenot said his company plans to begin a study later this year.

Companies: Incyte

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

How 5 orgs help local businesses achieve success

19 tech and entrepreneurship events to check out before the holidays

Technical.ly’s 2024 gift guide for Delaware

Technically Media